3CTN supports a portfolio of academic clinical trials that reflect the priorities of clinicians, researchers, patients, ministries of health and funders. Scientific oversight will be provided by the Portfolio Committee (PC) and management of the day-to-day operations is provided by the 3CTN Coordinating Centre. Academically sponsored trials that are included on the portfolio are eligible for 3CTN support.
3CTN aims to assist both clinicians/researchers and patients in finding cancer clinical trials that may be of benefit. Patients that are interested in participating in a clinical trial must contact their healthcare provider for details, but may wish to search the 3CTN Portfolio to know which trials are open to accrual at their local centre.
3CTN Portfolio Trial Listing
3CTN has created an interactive repository of trials to help you easily navigate through all past and present Portfolio trials.
View the 3CTN Portfolio Trial Listing
Watch a quick tutorial on how to use the 3CTN Portfolio Trial Listing here.
Learn about the Portfolio
Portfolio Trial Eligibility
- An eligible trial must meet the following criteria:
- Interventional oncology trial;
- Academically sponsored (Clinical Trial Applications held by academic institution);
- Open to multiple Canadian sites;
- Funded independently of 3CTN;
- Peer reviewed by external reviewers.
- For additional details, see the Trial Eligibility Criteria and Guidelines.
To submit a trial for consideration for the 3CTN Portfolio, complete the Application Form and submit to email@example.com. Trials will be assessed according to the Portfolio Process Map. If your cancer centre is using EDGE please submit your application through EDGE following these steps
If you have recently submitted a trial for review, please see the Portfolio Application Status Update Summary for a list of studies submitted to 3CTN for review and approval.
Facilitated Peer Review
The 3CTN Coordinating Centre can help facilitate peer review for an un-reviewed trial. Please see the documents listed below for further details:
Once a trial has been assessed and accepted on to the 3CTN Portfolio, a Network centre that has the opened the trial to accrual is eligible to receive per case funding (PCF) for those patients recruited above the centre’s established PCF trigger*
*as defined within individual contractual agreements between 3CTN and the Network centre site.
Per Case Funding Amounts
The PCF amount for 2018-2022 associated with each complexity rating:
|Trial Complexity Score||PCF Amount ($)**|
|≥ 7 (High) ||1000|
**PCF distribution is subject to available funding
Incentive Based Funding
3CTN’s funding model has been updated to include Incentive Based Funding (IBF) for Year 7 (April 1, 2020-March 31, 2021) and Year 8 (April 1, 2021-March 31, 2022).IBF rates are subject to funding availability. Please refer to the Incentive Based Funding Process for IBF factors and definitions.
Adapted from published literature, 3CTN created categories to describe the mix of trials that make up the Network’s Portfolio. The customized framework developed with the Portfolio Committee’s input was derived from “The Importance of Doing Trials Right While Doing the Right Trials” paper (Dilts et. Al.) and can allow for analyses based on a standardized set of Study Criteria as well as defined Impact on Patient Population and Innovativeness (see below).
Results from periodic review will enable assessments of the different types of studies being undertaken at a given point, trends and changes over time as well as help articulate the overall impact of the Portfolio for funders and other stakeholders.
View an interactive report on the outcomes of 3CTN’s Portfolio Impact Analysis.
Search the Portfolio
- Portfolio Trial Listing
- Search the Portfolio
- Portfolio Search Guide
- Portfolio Map: Ovarian
- 3CTN Portfolio Trials by Calendar Year
- Trial Eligibility Criteria and Guidelines
- Application Form
- Portfolio Process Map
- EDGE Portfolio Application Steps
- FPR Intake Form
- FPR Reviewer Guidelines
- FPR Reviewer Form
- Complexity Rating Guidelines
- Identification of Pediatric High Priority Trials
- Incentive Based Funding Process